Hematoxylin and eosin staining confirmed that the tumors had a morphologic structure that was compatible with GBM, and the Ki67 proliferation marker was quantified and shown to be significantly lower in mice treated with melatonin (Figure 4g,h). This evidence concerns the gene MKI67 and glioblastoma.